I caught that too when the PR came out. Since the PR was announcing Q1 results I believe when they said data released next quarter they were still referring to Q2 even though the PR was released in May. Hence the reason further down in the PR they say data will be released end of Q2.
The data in the active group was never going to be as good as the data in the adjuvant group. So far the active data we have seen, the 6 safety lead in patients, has tracked with the initial results from BCM so I would expect that to remain the same but don't expect improved results other than the addition of the MRD positive patients turning MRD negative. If active data stayed on track with the BCM data there was a chance they could still receive approval for it but the approach has now switched to MRD and turning the positive patients negative which will only lead to an increased chance of approval if they can prove their therapy is what is causing the change. That's what I'll be looking for in the data but it will still be a very small sample size. I believe it will be less than 10 patients reported on. They need the damn trial back up and running so they can have more data.
The adjuvant data is going to take longer because once the patients are dosed, they need to wait at least a year, if I remember correctly, to be evaluated. It’s possible we get some interim data prior to that point but I wouldn’t count on it. I would assume that the year timeline before evaluation is why the company has not given an estimate yet on when to expect data. We might get a small data release sometime end of this year or beginning of next year on the patients that have already been enrolled, somewhere around 10 patients, but the rest won’t be until end of next year with the delay to the current trial so long as they get it started back up again on their stated timeline.
News 
Market Data 
Discover 
